Intercostal pedicled flap in esophageal atresia.

C. Black,J. Raffensperger,L. Holinger

IF: 2.549

Journal of Pediatric Surgery

Abstract:

What problem does this paper attempt to address?

Synthesis and broad-spectrum antiproliferative activity of diarylamides and diarylureas possessing 1,3,4-oxadiazole derivatives.

M. M. Gamal El-Din,M. El‐Gamal,Mohammed S. Abdel‐Maksoud,K. Yoo,C. Oh

DOI: https://doi.org/10.1016/j.bmcl.2015.03.001

IF: 2.94

2015-04-15

Bioorganic & Medicinal Chemistry Letters

Abstract:
Diagnosis and management of gestational trophoblastic disease: 2021 update

Hextan Y. S. Ngan,Michael J. Seckl,Ross S. Berkowitz,Yang Xiang,François Golfier,Paradan K. Sekharan,John R. Lurain,Leon Massuger

DOI: https://doi.org/10.1002/ijgo.13877

2021-10-01

Abstract:Gestational trophoblastic disease (GTD) arises from abnormal placenta and is composed of a spectrum of premalignant to malignant disorders. Changes in epidemiology of GTD have been noted in various countries. In addition to histology, molecular genetic studies can help in the diagnostic pathway. Earlier detection of molar pregnancy by ultrasound has resulted in changes in clinical presentation and decreased morbidity from uterine evacuation. Follow-up with human chorionic gonadotropin (hCG) is essential for early diagnosis of gestational trophoblastic neoplasia (GTN). The duration of hCG monitoring varies depending on histological type and regression rate. Low-risk GTN (FIGO Stages I-III: score <7) is treated with single-agent chemotherapy but may require additional agents; although scores 5-6 are associated with more drug resistance, overall survival approaches 100%. High-risk GTN (FIGO Stages II-III: score ≥7 and Stage IV) is treated with multiagent chemotherapy, with or without adjuvant surgery for excision of resistant foci of disease or radiotherapy for brain metastases, achieving a survival rate of approximately 90%. Gentle induction chemotherapy helps reduce early deaths in patients with extensive tumor burden, but late mortality still occurs from recurrent treatment-resistant tumors.

obstetrics & gynecology
Stimulation of thyroid adenylate cyclase activity by sera from patients with non-thyroidal illness.

F. Kakezono,S. Yamashita,N. Yokoyama,S. Morita,I. Kubo,S. Ohtakara,S. Okamoto,I. Morimoto,N. Ikari,M. Izumi

DOI: https://doi.org/10.1530/ACTA.0.1130340

1986-11-01

Acta Endocrinologica

Abstract:We have previously shown that sera from many hypothyroid patients stimulated adenylate cyclase activity as measured by serum bioactive TSH concentrations produced by FRTL-5 cell line. This TSH-stimulating activity did not correlate with serum immunoreactive TSH. IgG fractions of these sera did not stimulate FRTL-5 cells. The present study was, therefore, undertaken to investigate the thyroid stimulating activity of sera from patients with non-thyroidal illness. Studies were performed in 36 patients with various non-thyroidal illness. In these patients, serum concentrations of T4, free thyroxine, T3, and TSH were determined. In addition, sera were incubated with FRTL-5 cells or porcine thyroid cells in primary culture in the presence of 0.4 mM MIBX, and medium cAMP concentrations were determined by radioimmunoassay. Sera obtained from some patients with various non-thyroidal illness increased cAMP concentrations in culture media of FRTL-5 cells as well as that of porcine thyroid cells. The thyroid stimulating effects of sera were not disease specific and significantly correlated inversely with serum T3 and T4 concentrations. Serum TSH concentrations in these patients were within the normal range even by the newly developed ultrasensitive assay. Although the nature of substance(s) present in sera of patients with low T3 syndrome which stimulates thyroid adenylate cyclase is not entirely known, it is conceivable that there exist mechanisms independent of TSH to compensate the decreased serum T3 levels in low T3 syndrome.
Update on the diagnosis and management of gestational trophoblastic disease

Hextan Y.S. Ngan,Michael J. Seckl,Ross S. Berkowitz,Yang Xiang,François Golfier,Paradan K. Sekharan,John R. Lurain,Leon Massuger

DOI: https://doi.org/10.1002/ijgo.12615

2018-10-01

Abstract:Gestational trophoblastic disease (GTD) arises from abnormal placenta and is composed of a spectrum of premalignant to malignant disorders. Changes in epidemiology of GTD have been noted in various countries. In addition to histology, molecular genetic studies can help in the diagnostic pathway. Earlier detection of molar pregnancy by ultrasound has resulted in changes in clinical presentation and decreased morbidity from uterine evacuation. Follow-up with human chorionic gonadotropin (hCG) is essential for early diagnosis of gestational trophoblastic neoplasia (GTN). The duration of hCG monitoring varies depending on histology type and regression rate. Low-risk GTN (FIGO Stages I-III: score <7) is treated with single-agent chemotherapy but may require additional agents; although scores 5-6 are associated with more drug resistance, overall survival approaches 100%. High-risk GTN (FIGO Stages II-III: score >7 and Stage IV) is treated with multiple agent chemotherapy, with or without adjuvant surgery for excision of resistant foci of disease or radiotherapy for brain metastases, achieving a survival rate of approximately 90%. Gentle induction chemotherapy helps reduce early deaths in patients with extensive tumor burden, but late mortality still occurs from recurrent resistant tumors.

obstetrics & gynecology
Clinical analysis of recurrent gestational trophoblastic neoplasia

Zhou Wei,Qian Jianhua,Chen Yaxia

DOI: https://doi.org/10.13283/j.cnki.xdfckjz.2011.01.026

2011-01-01

Abstract:Objectives:To analyze retrospectively clinical character of recurrent gestational trophoblastic neoplasia(GTN)and discuss the management of these patients.Method:Clinical data of 21 cases of recurrent gestational trophoblastic neoplasia from June 1st,2000 to June 1st,2009 in Women's Hospital Affiliated to School of Medicine of Zhejiang University were retrospectively analyzed,and the management with these cases were further discussed.Results:In the 21 cases,recurrence interval ranged from 2 months to 20 years.16 cases(76.2%) were single recurrence,and the other 5 cases(23.8%) relapsed 2 times or more than 2 times.Relapsed gestational trophoblastic neoplasia had been treated in our hospital.In the 21 cases,12 cases(57.1%) relapsed within 12 months;and 9 cases(40.9%) relapsed after 12 months(4 cases relapsed between 12 to 24 months).In the 16 single recurrence cases,13 cases used chemotherapy with EMA-CO regimen,and 10 cases were in SCR after 3～7 cycles treatment.2 cases were replaced whit EP-EMA regimen(1 case whit surgical adjuvant therapy)and achieved SCR after 5 cycles treatment.1 case refused to continue treatment.In the 5 multiple relapsed cases,4 cases were 2 times recurence and 1 case was 3 times recurrence.In the 4 cases,3 cases were in SCR after 5～10 cycles with EMA-CO regimen and 1 case gave up treatment after surgery.The case of 3 times recurrence reached the SCR after every treatment.In the 21 cases,10 cases(47.6%) used surgical adjuvant therapy.5 cases underwent hysterectomy at initial treatment.In the 7 surgery cases,3 cases underwent hysterectomy;1 case uterine lesions excision;and 2 cases metastas excision(hysterectomy as initial treatment);and 1 case underwent successively metastas excision and hysterectomy at the time of local relapse.These cases achieved remission to some degree after surgical treatment.Conclusion:EMA-based combination chemotherapy is effective in GTN patients.Surgery can be used as supplementary treatment for recurrent GTN.
Diffusing capacity of the lung during hypoxia: role of capillary recruitment.

R. Capen,L. Latham,W. Wagner

DOI: https://doi.org/10.1152/JAPPL.1981.50.1.165

Abstract:We have used in vivo microscopy to show that airway hypoxia caused pulmonary capillary recruitment. To determine whether the recruited capillaries add to the surface area for gas exchange, we measured the diffusing capacity of the lung for carbon monoxide before and after inducing recruitment with hypoxia. Diffusing capacity increased during hypoxia. However, some increase in diffusing capacity was expected, since there were fewer oxygen molecules to compete with carbon monoxide for hemoglobin-binding sites. To determine the effect of capillary recruitment alone on diffusing capacity, we held hypoxia constant while infusing a vasodilator to diminish recruitment. Diffusing capacity decreased concomitantly as recruitment diminished. These results indicate that our microscopic observations reflect a widespread recruitment that increases the gas exchange surface area.
Are People Aware of Oral and Maxillofacial Surgery in India?

K. Reddy,S. Adalarasan,S. Mohan,P. Sreenivasan,A. Thangavelu

DOI: https://doi.org/10.1007/s12663-011-0208-y

2011-05-06

Journal of Maxillofacial and Oral Surgery

Abstract:
[GESTATIONAL TROPHOBLASTIC DISEASE: THE NEED FOR CENTRALIZATION OF TREATMENT CENTERS IN ISRAEL]

Inbal Marom,Ofer Lavie,Meirav Schmidt,Ludmila Ostrovsky,Yakir Segev

Abstract:Gestational trophoblastic disease comprises a spectrum of pregnancy-related disorders, consists of premalignant disorders of complete and partial hydatidiform mole, and malignant disorders such as invasive mole, choriocarcinoma, and the rare placental-site trophoblastic tumor/epithelioid trophoblastic tumor. These malignant forms are termed Gestational Trophoblastic Neoplasia (GTN). Until the early 1960's, hysterectomy was the treatment of choice for women with malignant trophoblastic diseases. The five-year survival rate was 40% for local disease, and around 20% in women with metastases. Chemotherapy, treatment according to the various risk factors and the use of β-hCG values as a marker for monitoring the disease, resulted in a cure rate exceeding 98%, while preserving patient's fertility. Due to its` extremely low incidence with relatively complex treatment protocols, in the presence of high potential for side effects, in most countries there are tertiary centers that coordinate the treatment and follow-up of these diseases. In this review, we will summarize strategies for the primary management of gestational trophoblastic disease, the evaluation and management of malignant gestational trophoblastic neoplasia (GTN) and surveillance after treatment.
Erythroderma: Not Your Everyday Sunburn.

A. Grock,Brittney Declerck,M. Herbert,Paul Jhun

DOI: https://doi.org/10.1016/j.annemergmed.2017.01.028

IF: 6.762

2017-03-01

Annals of Emergency Medicine

Abstract:
Clinical Features of 17 Cases of Placental Site Trophoblastic Tumor

Yaxia Chen,Xiuli Zhang,Xing Xie

DOI: https://doi.org/10.1016/j.ijgo.2011.06.008

2011-01-01

Abstract:International Journal of Gynecology & ObstetricsVolume 115, Issue 2 p. 204-205 Brief communications Clinical features of 17 cases of placental site trophoblastic tumor Yaxia Chen, Corresponding Author Yaxia Chen [email protected] Department of Gynecologic Oncology, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, ChinaCorresponding author at: Department of Gynecologic Oncology, Women's Hospital, School of Medicine, Zhejiang University, 2 Xueshi Road, Hangzhou 310006, China. Tel.: + 86 571 87061501x2151/13575737780; fax: + 86 571 87036290.Search for more papers by this authorXiuli Zhang, Xiuli Zhang Department of Gynecologic Oncology, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, ChinaSearch for more papers by this authorXing Xie, Xing Xie Department of Gynecologic Oncology, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, ChinaSearch for more papers by this author Yaxia Chen, Corresponding Author Yaxia Chen [email protected] Department of Gynecologic Oncology, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, ChinaCorresponding author at: Department of Gynecologic Oncology, Women's Hospital, School of Medicine, Zhejiang University, 2 Xueshi Road, Hangzhou 310006, China. Tel.: + 86 571 87061501x2151/13575737780; fax: + 86 571 87036290.Search for more papers by this authorXiuli Zhang, Xiuli Zhang Department of Gynecologic Oncology, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, ChinaSearch for more papers by this authorXing Xie, Xing Xie Department of Gynecologic Oncology, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, ChinaSearch for more papers by this author First published: 08 September 2011 https://doi.org/10.1016/j.ijgo.2011.06.008Citations: 14Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. References [1]Hassadia A., Gillespie A., Tidy J., Everard R.G.N.J., Wells M., Coleman R., et al. Placental site trophoblastic tumour: clinical features and management. Gynecol Oncol. 99(3): 2005; 603–607 10.1016/j.ygyno.2005.06.054 PubMedWeb of Science®Google Scholar [2]Papadopoulos A.J., Foskett M., Seckl M.J., McNeish I., Paradinas F.J., Rees H., et al. Twenty-five years' clinical experience with placental site trophoblastic tumors. J Reprod Med. 47(6): 2002; 460–464 PubMedWeb of Science®Google Scholar [3]Schmid P., Nagai Y., Agarwal R., Hancock B., Savage P.M., Sebire N.J., et al. Prognostic markers and long-term outcome of placental-site trophoblastic tumours: a retrospective observational study. Lancet. 374(9683): 2009; 48–55 10.1016/S0140-6736(09)60618-8 CASPubMedWeb of Science®Google Scholar [4]Benedet J.L., Bender H., Jones H. III, Ngan H.Y., Pecorelli S., FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynecol Obstet. 70(2): 2000; 209–262 10.1016/S0020-7292(00)90001-8 CASPubMedWeb of Science®Google Scholar Citing Literature Volume115, Issue2November 2011Pages 204-205 ReferencesRelatedInformation
The role of surgery in gestational trophoblastic disease: an overview

Joseph S Ng,Arunachalam Ilancheran

DOI: https://doi.org/10.1136/ijgc-2023-004584

2024-03-04

International Journal of Gynecological Cancer

Abstract:Gestational trophoblastic disease comprises a group of rare, and potentially malignant, conditions that arise from abnormal trophoblastic proliferation. When there is invasion and evidence of metastatic disease, gestational trophoblastic neoplasia is used. While chemotherapy is the mainstay of treatment for gestational trophoblastic neoplasia, the role of surgery has come full circle in recent years. Before the introduction of highly effective systemic treatment options, surgery was the default treatment. Surgery for gestational trophoblastic neoplasia often yielded unsatisfactory results and mortality remained high. In recent years, the role of adjuvant surgery in the management of gestational trophoblastic neoplasia has been examined with great interest. We aim to provide an overview of the various surgical approaches employed in managing gestational trophoblastic neoplasia, including their indications, techniques, and outcomes. Additionally, we discuss whether there is a role to do less in surgery for gestational trophoblastic neoplasia and describe our experience with a modified surgical technique for its treatment. By summarizing the current evidence, this article highlights the significant contributions of surgery to the holistic management of patients with gestational trophoblastic neoplasia and provides a framework on which to base management and treatment programs.

oncology,obstetrics & gynecology
Six types of neurotic reaction to a husband's request for a divorce.

E. Bergler

DOI: https://doi.org/10.2307/348335

Marriage and Family Living

Abstract:
Guidelines and multidisciplinary care are essential to improve survival rates and quality of life globally for women with Gestational Trophoblastic Disease

Christianne Lok,Michael Seckl

DOI: https://doi.org/10.1159/000539107

2024-04-26

Gynecologic and Obstetric Investigation

Abstract:abstract is not required for editorial

obstetrics & gynecology
Review of current literature on gestational trophoblastic neoplasia

Mehwish Shahzadi,Saqib Raza Khan,Muhammad Tariq,Sehrish Sarwar Baloch,Aisha Shahid,Munira Moosajee,Zarka Samon

DOI: https://doi.org/10.1186/s43046-023-00195-y

2023-11-27

Abstract:Background: Gestational Trophoblastic Neoplasia (GTN) is a disease of the reproductive age group with an incidence rate of <1% among all tumors involving the female reproductive tract. It occurs because of aberrant fertilization. Patients are diagnosed early because of aggravated symptoms during pregnancy. Moreover, patients also bleed from the tumor sites, which leads to early presentation. A cure rate of 100% can be achieved with adequate treatment. Main body: In this literature review, the authors have brought to attention the risk factors, classification, and various treatment options in GTN patients according to their stratification as per the WHO scoring system. Patients are categorized into low and high risk based on the FIGO scoring system. Patients with low risk are treated with single-agent methotrexate or actinomycin-D. Despite the superiority of actinomycin-D in terms of efficacy, methotrexate remains the first choice of therapy in low-risk patients due to its better toxicity profile. Multi-agent chemotherapy with etoposide, methotrexate, actinomycin-D, cyclophosphamide and vincristine (EMA-CO) leads to complete remission in 93% of high-risk GTN patients. Around 40% of patients with incomplete responses are salvaged with platinum-based multi-agent chemotherapy. Isolated chemo-resistant clones can be salvaged with surgical interventions. Conclusion: The mortality in patients with GTN has significantly reduced over time. With adequate multi-disciplinary support, patients with GTN can ultimately be cured and can spend every day healthy reproductive life.
Separation and purification by two-dimensional gel electrophoresis of a 52-54 kDa bumetanide binding protein from rat liver plasma membranes.

W. Honscha,M. Ottallah,Achim Schenk,K. Schuh,E. Petzinger

DOI: https://doi.org/10.1016/0922-4106(92)90064-3

IF: 5.195

1992-07-01

European Journal of Pharmacology

Abstract:
[Effects of Primary Chemotherapy with Single Methotrexate on Low-Risk Gestational Trophoblastic Neoplasia and Influencing Factors Thereof].

Ya-xia Chen,Yuan-ming Shen,Jian-hua Qian,Xing Xie

DOI: https://doi.org/10.3760/j:issn:0376-2491.2005.30.007

2005-01-01

Abstract:OBJECTIVE To evaluate the effects of primary chemotherapy with single-agent methotrexate (MTX) on low-risk gestational trophoblastic neoplasia (GTN) and the influencing factors thereof. METHODS Sixty-one GTN patients with the score of < or = 6 according to the new International Federation of Gynecology and Obstetrics (FIGO) scoring system (2000) were divided into 2 groups: 51 patients were treated with single MTX 0.4 mg/kg daily for 5 days (MTX 5 d group), and 10 patients were treated with MTX on the days 1, 3, 5, and 7, and with folinic acid (FA) 0.1 mg/kg on the days 2, 4, 6, and 8 (MTX + FA group), both group with an interval of treatment course of 2 weeks. The serum level of human chorionic gonadotropin (hCG) was detected every week. If a plateau or increase of serum hCG appeared between 2 examination results, meaning tolerance to MTX, the patients concerned had to undergo different regimens of salvage chemotherapy, all with MTX as one of their components. Univariate and multivariate methods were used to analyze the relationships of different factors to the outcomes of chemotherapy. RESULTS Thirty-five of the 51 patients of the MTX 5d group (68.6%) achieved complete primary remission, 3 of the 10 patients of the MTX + FA group achieved complete primary remission, and all patients achieved complete remission after salvage chemotherapy. Univariate analysis showed that the mean pretreatment serum level of hCG, duration between antecedent pregnancy and start of treatment, size of tumor, FIGO score, specific regimen of MTX were significantly associated with outcome of chemotherapy (P = 0.004, 0.022, 0.017, 0.005, 0.021 respectively). Logistic regression analysis showed that only three independent factors predictive for the outcome of chemotherapy: MTX regimen (OR = 2.476), FIGO score (OR = 1.431), and pretreatment hCG titer (OR = 1.001). CONCLUSION Primary chemotherapy with single MTX regimen may still be one of the options for patients with low-risk GTN according to the new FIGO scoring system, though the rate of complete primary remission appears to be lower. All patients with low-risk GTN achieve complete remission after salvage chemotherapy. MTX regimen, FIGO score, and pretreatment hCG are independent risk factors of outcome of single MTX chemotherapy.
Clinicopathological Characteristics and Treatment Outcomes of Pregnancy Complicated by Malignant Ovarian Germ Cell Tumors.

Xuan Zong,Jia-Xin Yang,Ying Zhang,Dong-Yan Cao,Keng Shen

DOI: https://doi.org/10.2147/cmar.s240793

2020-01-01

Cancer Management and Research

Abstract:PURPOSE:This study aimed to analyze the clinicopathological features, treatment, and feto-maternal outcomes of pregnancy complicated by malignant ovarian germ cell tumors (MOGCTs), to increase the awareness on this condition.PATIENTS AND METHODS:We retrospectively reviewed the medical records of patients diagnosed with MOGCTs during pregnancy, who were treated and followed-up at Peking Union Medical College Hospital from January 2000 to December 2017. The demographic characteristics, pathological features, treatment and prognosis were analyzed.RESULTS:The histological subtypes varied in 14 patients (dysgerminoma, n=1; immature teratoma, n=4; yolk sac tumor, n=6; and mixed germ cell tumors, n=3). Ten (71.4%) patients, including three who opted for conservative therapy until childbirth, one who only received salvage chemotherapy during pregnancy, and six who underwent cystectomy or unilateral salpingo-oophorectomy during pregnancy, desired fetal preservation. After undergoing surgery, four patients chose surveillance instead of timely adjuvant chemotherapy. Eight patients delivered their babies, and the preterm delivery rate was 50.0%. One newborn died of premature birth. The median follow-up period was 44 (range: 13 to 86) months. During the current study period, 12 patients had survived and did not report any diseases. However, two died due to disease progression.CONCLUSION:Pregnant women with MOGCTs had favorable outcomes. However, when a malignant tumor is suspected, surgery cannot be avoided. Thus, instead of timely postoperative adjuvant chemotherapy, close surveillance may be an acceptable alternative for pregnant women with low-risk MOGCTs.
Diagnosis and management of or recurrent resistant gestational trophoblastic neoplasia

Wei-guo L(U)

DOI: https://doi.org/10.3760/cma.j.issn.1008-1372.2016.09.051

2015-01-01

Abstract:With the application of chemotherapy,gestational trophoblastic neoplasia (GTN) has been the first of malignant tumors which can be cured by chemotherapy.However,the resistance and relapse still is the difficulty of treatment and the leading cause of death in patients.Approximately 20％～ 30％ of GTN tumor will be resistant to,or will relapse after cure.These resistant and relapsed lesions will require salvage therapy,which be treated with multi-agent chemotherapy with or without surgery and/or adjuvant radiation therapy.Various salvage regimens are used worldwide.It is unclear to determine which of the various salvage combinations,if any,was the most effect and the least toxic for the treatment of resistant or relapsed GTN.
Guideline No. 414: Management of Pregnancy of Unknown Location and Tubal and Nontubal Ectopic Pregnancies

Leslie Po,Jacqueline Thomas,Kelsey Mills,Andrew Zakhari,Togas Tulandi,Mira Shuman,Andrea Page

DOI: https://doi.org/10.1016/j.jogc.2021.01.002

Abstract:Objective: To provide an evidence-based algorithm to guide the diagnosis and management of pregnancy of unknown location and tubal and nontubal ectopic pregnancy. Target population: All patients of reproductive age. Benefits, harms, and costs: The implementation of this guideline aims to benefit patients with positive β-human chorionic gonadotropin results and provide physicians with a standard algorithm for expectant, medical, and surgical treatment of pregnancy of unknown location and tubal pregnancy and nontubal ectopic pregnancies. Evidence: The following search terms were entered into PubMed/Medline and Cochrane in 2018: cesarean section, chorionic gonadotropin, beta subunit, human/blood, fallopian tubes/surgery, female, fertility, humans, infertility, laparoscopy, methotrexate, methotrexate/administration & dosage, methotrexate/therapeutic use, pregnancy (abdominal, angular, cervix, cornual, ectopic, ectopic/diagnosis, ectopic/diagnostic imaging, ectopic/drug therapy, ectopic/epidemiology, ectopic/mortality, ectopic/surgery, heterotopic, interstitial, isthmo-cervical, ovarian, tubal, unknown location), recurrence, risk factors, salpingectomy, salpingostomy, tubal pregnancy, ultrasonography, doppler ultrasonography, and prenatal. Articles included were randomized controlled trials, meta-analyses, systematic reviews, observational studies, and case reports. Additional publications were identified from the bibliographies of these articles. Only English-language articles were reviewed. Validation methods: The authors rated the quality of evidence and strength of recommendations using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach. See online Appendix A (Tables A1 for definitions and A2 for interpretations of strong and weak recommendations). Intended audience: Obstetrician-gynaecologists, family physicians, emergency physicians, midwives, registered nurses, nurse practitioners, medical students, and residents and fellows. Summary statements (grade ratings in parentheses): RECOMMENDATIONS (GRADE RATINGS IN PARENTHESES).
[Curative Effects and Influenced Factors of Primary Chemotherapy with Single-Agent Methotrexate on Low-Risk Gestational Trophoblastic Neoplasia].

X D Wu,L,T Shen,S,Q,J L Qin,Y F Fu,W G Lü

DOI: https://doi.org/10.3760/cma.j.issn.0376-2491.2017.23.003

2017-01-01

Abstract:Objective: To evaluate the efficacy of primary chemotherapy with single-agent methotrexate (MTX) for low-risk gestational trophoblastic neoplasia and to analysis the influenced factors. Methods: We retrospectively reviewed 259 cases with low-risk gestational trophoblastic neoplasia whose primary chemotherapies were MTX 0.4 mg·kg(-1) (maximum 25 mg) daily for 5 days every other week. Patients' data between January 2001 and June 2015 was collected and the relationships of different factors to outcomes of chemotherapy were also evaluated. Results: 183 of the 259 patients (70.66%, 183/259) achieved complete primary remission and all patients achieved complete remission after salvage chemotherapy. Univariate analysis showed that FIGO score, serum level of HCG before treatment and interval months from previous pregnancy were significantly associated with outcome of chemotherapy (P=0.001, 0.018, 0.014 respectively). Logistic regression analysis showed that the FIGO score (OR=4.094) and antecedent pregnancy (OR=0.268) were two independent factors predictive for the outcome of chemotherapy. Conclusions: Primary chemotherapy with single-agent MTX may still be one of the options for patients with low risk GTN. The FIGO score and antecedent pregnancy are two independent risk factors of outcome of single-agent MTX chemotherapy.

Intercostal pedicled flap in esophageal atresia.

Synthesis and broad-spectrum antiproliferative activity of diarylamides and diarylureas possessing 1,3,4-oxadiazole derivatives.

Diagnosis and management of gestational trophoblastic disease: 2021 update

Stimulation of thyroid adenylate cyclase activity by sera from patients with non-thyroidal illness.

Update on the diagnosis and management of gestational trophoblastic disease

Clinical analysis of recurrent gestational trophoblastic neoplasia

Diffusing capacity of the lung during hypoxia: role of capillary recruitment.

Are People Aware of Oral and Maxillofacial Surgery in India?

[GESTATIONAL TROPHOBLASTIC DISEASE: THE NEED FOR CENTRALIZATION OF TREATMENT CENTERS IN ISRAEL]

Erythroderma: Not Your Everyday Sunburn.

Clinical Features of 17 Cases of Placental Site Trophoblastic Tumor

The role of surgery in gestational trophoblastic disease: an overview

Six types of neurotic reaction to a husband's request for a divorce.

Guidelines and multidisciplinary care are essential to improve survival rates and quality of life globally for women with Gestational Trophoblastic Disease

Review of current literature on gestational trophoblastic neoplasia

Separation and purification by two-dimensional gel electrophoresis of a 52-54 kDa bumetanide binding protein from rat liver plasma membranes.

[Effects of Primary Chemotherapy with Single Methotrexate on Low-Risk Gestational Trophoblastic Neoplasia and Influencing Factors Thereof].

Clinicopathological Characteristics and Treatment Outcomes of Pregnancy Complicated by Malignant Ovarian Germ Cell Tumors.

Diagnosis and management of or recurrent resistant gestational trophoblastic neoplasia

Guideline No. 414: Management of Pregnancy of Unknown Location and Tubal and Nontubal Ectopic Pregnancies

[Curative Effects and Influenced Factors of Primary Chemotherapy with Single-Agent Methotrexate on Low-Risk Gestational Trophoblastic Neoplasia].